Author

Ling Qi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Safety of eribulin: A real-world study based on a pharmacovigilance database

Eribulin is used to treat metastatic breast cancer, but its adverse event (AE) profile requires comprehensive analysis using FDA Adverse Event Reporting System (FAERS) data to guide clinical use. We analyzed eribulin-related AE reports in FAERS (Q1 2011 - Q2 2024). Disproportionality analyses (ROR, PRR, MGPS, BCPNN) id...

Yao Zhou, Jie Gong, Le-Le Shen et al. · PLoS ONE · 0 citations

Review Open access Sep 2026

Indole hybrids as promising anti-hepatocellular carcinoma agents: a comprehensive review of recent advances and therapeutic prospects.

The current landscape of indole hybrids developed from 2021 to the present that exhibit anti-HCC potential are summarized, aiming to open new avenues for the discovery of novel anti-HCC candidates.

Xiao-Guang Jiang, Ben-Tao Jia, Xiao-Tong Yang et al. · Future Medicinal Chemistry · 0 citations